Alkermes (ALKS) Income from Non-Controlling Interests (2011 - 2012)
Alkermes (ALKS) posted quarterly Income from Non-Controlling Interests of $594000.0 for Q3 2012, up 343.44% year-over-year from $133951.9 in Q4 2011, and up 343.44% quarter-over-quarter from -$244000.0 in Q3 2011.
Alkermes (ALKS) Income from Non-Controlling Interests (2011 - 2012) Analysis & Trends
Alkermes (ALKS) has reported Income from Non-Controlling Interests for 2 consecutive years, with $594000.0 the latest figure, recorded in Q3 2012.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.79 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.38 Bn | 39.73 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.61 Bn | 29.93 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn | 376,434.15 |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.82 Bn | 17.93 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | - |
| 10 | Alkermes | 8.21 Bn | 7.55 Bn | 397.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2012 | 594,000.00 |
| Sep 30, 2011 | -244,000.00 |